The Op­di­vo-Yer­voy com­bo from Bris­tol My­ers is work­ing to­ward ap­proval in first-line liv­er can­cer

Bris­tol My­ers Squibb is work­ing to­ward its ninth ap­proval for its Op­di­vo-Yer­voy com­bi­na­tion, this time in the first-line set­ting for ad­vanced liv­er can­cer.

In topline Phase 3 da­ta re­leased Wednes­day, the com­bi­na­tion met its pri­ma­ry end­point, over­all sur­vival, at an in­ter­im analy­sis as a first-line treat­ment for pa­tients with ad­vanced he­pa­to­cel­lu­lar car­ci­no­ma. He­pa­to­cel­lu­lar car­ci­no­ma is the most com­mon type of pri­ma­ry liv­er can­cer and ac­counts for 90% of all liv­er can­cers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.